Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis.
about
Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicityTherapeutic neuroprotective agents for amyotrophic lateral sclerosisChronic administration of AMD3100 increases survival and alleviates pathology in SOD1(G93A) mice model of ALSDoes neuroinflammation fan the flame in neurodegenerative diseases?Chemokine MIP-2/CXCL2, acting on CXCR2, induces motor neuron death in primary culturesEvaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis.Redox modifier genes and pathways in amyotrophic lateral sclerosis.NP001 regulation of macrophage activation markers in ALS: a phase I clinical and biomarker studyDifferential gene expression in the axotomized facial motor nucleus of presymptomatic SOD1 miceA comparison of in vitro properties of resting SOD1 transgenic microglia reveals evidence of reduced neuroprotective functionNeuronal cellular responses to extremely low frequency electromagnetic field exposure: implications regarding oxidative stress and neurodegenerationBee venom attenuates neuroinflammatory events and extends survival in amyotrophic lateral sclerosis models.Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS).Glycogen synthase kinase-3β inactivation inhibits tumor necrosis factor-α production in microglia by modulating nuclear factor κB and MLK3/JNK signaling cascadesProgress in therapy development for amyotrophic lateral sclerosisTherapeutic potential of mesenchymal stromal cells and MSC conditioned medium in Amyotrophic Lateral Sclerosis (ALS)--in vitro evidence from primary motor neuron cultures, NSC-34 cells, astrocytes and microglia.Early-stage treatment with Withaferin A reduces levels of misfolded superoxide dismutase 1 and extends lifespan in a mouse model of amyotrophic lateral sclerosis.Alsin and SOD1(G93A) proteins regulate endosomal reactive oxygen species production by glial cells and proinflammatory pathways responsible for neurotoxicityDeath Receptors in the Selective Degeneration of Motoneurons in Amyotrophic Lateral Sclerosis.Patient-derived olfactory mucosa for study of the non-neuronal contribution to amyotrophic lateral sclerosis pathology.Humoral factors in ALS patients during disease progression.Impaired expression of insulin-like growth factor-1 system in skeletal muscle of amyotrophic lateral sclerosis patients.Complex Inflammation mRNA-Related Response in ALS Is Region DependentAmyotrophic lateral sclerosis: contemporary concepts in etiopathogenesis and pharmacotherapy.RNAseq Analyses Identify Tumor Necrosis Factor-Mediated Inflammation as a Major Abnormality in ALS Spinal Cord.Tumor necrosis factor-alpha and neuronal development.Gene expression profiling in peripheral blood mononuclear cells from patients with sporadic amyotrophic lateral sclerosis (sALS)Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases.Deletion of galectin-3 exacerbates microglial activation and accelerates disease progression and demise in a SOD1(G93A) mouse model of amyotrophic lateral sclerosisApoptotic death of neurons exhibiting peripherin aggregates is mediated by the proinflammatory cytokine tumor necrosis factor-alpha.Motor neuron-immune interactions: the vicious circle of ALS.Inter- and intracellular signaling in amyotrophic lateral sclerosis: role of p38 mitogen-activated protein kinase.6-Mercaptopurine attenuates tumor necrosis factor-α production in microglia through Nur77-mediated transrepression and PI3K/Akt/mTOR signaling-mediated translational regulationRole of zinc in ALS.Intraperitoneally administered IgG from patients with amyotrophic lateral sclerosis or from an immune-mediated goat model increase the levels of TNF-α, IL-6, and IL-10 in the spinal cord and serum of mice.Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis.Protein biomarkers for amyotrophic lateral sclerosis.Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trialNF-κB and IRF1 Induce Endogenous Retrovirus K Expression via Interferon-Stimulated Response Elements in Its 5' Long Terminal RepeatIncreased prevalence of autoimmune disease within C9 and FTD/MND cohorts: Completing the picture.
P2860
Q21284512-E7CC2779-4277-44B2-9C6D-AC0498E0F346Q27015029-E650CFDA-7492-4B0B-B7E9-F7E16E3A8C24Q27303112-BD930D8C-5A05-4E16-8E86-2EB90B7CD151Q27498993-BD269CCD-3B16-47DA-9FAA-C7139EEDCD2FQ28581270-24DDBA82-7582-4A40-A592-8E53B166B18FQ33689422-7AD44127-B858-4E66-86F4-93C21D390083Q33742737-D4B534C4-EFF3-4C0E-A667-EAAEB90383D7Q33924917-3063FC47-5B8A-4616-A859-B5CBAC5241D6Q33975101-FF79E293-8F99-4254-ADAF-61874E20F972Q34029114-108182B0-2980-431C-916B-3E259C7ED009Q34050769-62A22668-D7AE-4737-860B-D626FB35A900Q34282683-48D6333C-5E81-48B4-AB00-9F7F6627211AQ34369439-08E0D730-9654-405E-9FD6-5ADAAEED71E3Q34499838-B942F224-A37A-4798-9395-A8FC43990CACQ34640800-E2D978D3-39C6-4214-8691-E705279F6B32Q34998538-BE35BF03-1ECE-4021-9F33-56BEE538941FQ35064952-FB5099B1-515C-4464-9E18-641CF9FEE7C1Q35562672-13387BD9-BB32-462D-A7E1-44C797D1949EQ35623419-A2562163-5A68-4610-8DFC-D5DADA77E868Q35695531-19AEB59A-85CE-4307-A501-572E3D137B84Q35806256-D3515C68-2778-4DE2-B416-6D7FB72954FDQ35837412-4CA97ADB-7404-453D-B3B0-BC70D906653FQ35957868-CCC99CFD-E79C-451C-8A91-F64611ED3501Q35964723-04E1048F-A09C-48E2-943B-2FFD0061287EQ36093828-FA460F88-ACA8-4F05-A228-02FB31D56D4BQ36215202-D1375392-CDB4-4BB1-AEE9-C1B811AEC5E3Q36251872-0FEE954A-BF76-4CE6-97D8-88FC54F5E54AQ36330960-72A96206-D775-4132-BF81-A8CD20610631Q36373508-40F5932A-044B-4A8B-9410-45A1A3BF7E60Q36380025-F0CE58C3-497F-42C5-9840-CB0C5BBFE9E5Q36437332-B2B505F7-1036-4794-A5D2-7C097715448EQ36565649-0311E9F3-7C4A-4DAF-936C-98355240FA84Q36796853-2A38E514-2131-4A60-A1B1-4C3597DE8D4DQ36835575-AE9C680C-1FF1-4E22-9338-EA9997ECE386Q36934383-5FBCEFFE-5F66-43F5-994D-4BC750DA3E13Q36981080-C910AB0F-C6AD-4F8E-A874-E7843D096EE6Q37157841-A7D897CC-ED06-4992-A9CF-798D86906AC2Q37288200-24698798-4D3D-4087-A689-E504FB3F4456Q37300387-B36D3E3D-C0F8-4657-A8A1-5B108004A6B9Q37380290-2D229144-171B-41ED-A816-A178E24495C5
P2860
Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Circulating levels of tumour n ...... amyotrophic lateral sclerosis.
@en
type
label
Circulating levels of tumour n ...... amyotrophic lateral sclerosis.
@en
prefLabel
Circulating levels of tumour n ...... amyotrophic lateral sclerosis.
@en
P2093
P1433
P1476
Circulating levels of tumour n ...... amyotrophic lateral sclerosis.
@en
P2093
Agnoletti L
Bachetti T
Facchetti D
Francolini G
P304
P356
10.1016/S0304-3940(00)01177-0
P407
P577
2000-06-01T00:00:00Z